image goes here
Biosafety, Ethical, and Logistical Challenges to Pursuing a Coronavirus Vaccine at Warp Speed
The SARS-CoV-2 pandemic has impacted all aspects of society. Various government and private groups around the world are endeavoring to develop safe and effective vaccines at an unprecedented pace and scale to quell the pandemic as quickly as possible. In addition, the first COVID-19 vaccines approved leveraged novel messenger RNA (mRNA) technologies. With Advarra’s IRB and IBC experience in supporting 100% of Operation Warp Speed vaccine clinical trials, we have insight on the challenges faced while working in support of the goal to deliver safe and effective COVID-19 vaccines to the American public as quickly as possible.
In our upcoming webinar, Advarra experts Daniel Eisenman, Director of Biosafety Services, and Luke Gelinas, IRB Chair, share the biosafety, ethical, and logistical challenges faced throughout the research process of developing COVID-19 vaccines.
Learning Objectives:
- Understand the vaccine development challenges posed by the pandemic
- Learn how to perform risk assessments for genetically engineered COVID-19 vaccines
- Discuss the ethical considerations
- Evaluate status and challenges ahead, including second generation COVID-19 vaccine trials
Presented By
Daniel Eisenman
PhD, RBP, SM(NRCM), CBSP
Director of Biosafety Services
Advarra
Luke Gelinas
PhD
IRB Chair
Advarra
NA
NA
NA
NA
NA
NA
NA
DATE: February 11, 2021
Time: 1 pm ET | 10 am PT
Duration: 1 hour